Quick Read – JNJ raised full-year guidance and absorbed $330M in talc charges while Pfizer bet $7B on GLP-1 obesity assets to offset collapsing COVID revenue. – JNJ’s 64-year dividend streak, 46% payout ratio, and $21B free cash flow target make talc litigation noise a buying…
portunity, not a warning sign. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike. JNJ raised guidance while headlines fixated on a 68,000-case talc litigation MDL. Pfizer reaffirmed its outlook and pushed harder into obesity and oncology.
Two large-cap dividend payers, two very different setups for buyers today. Oncology Powers JNJ. Padcev and Vyndaqel Carry Pfizer.